anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCT No. PCT/FR90/00395 Sec. 371 Date Jan. 31, 1992 Sec. 102(e) Date Jan. 31, 1992 PCT Filed Jun. 5, 1990 PCT Pub. No. WO90/15051 PCT Pub. Date Dec. 13, 1990.A method for intercepting an activated species of dioxygen by administering an N-substituted pyrrole derivative having the formula:  (* CHEMICAL STRUCTURE *)  in which: R is an amino acid derivative, a non-protein peptide, an amino sugar processing a free primary amino group, a purine bases which is substituted, at position 9 by alkyl groups, or a pyrimidine bases possessing a free primary amino group, wherein the pyrimidine bases are substituted by at least one SH group; R1 represents one or more substituents, identical or different and are a hydrogen, an alkyl radical containing from 1 to 6 carbon atoms, a primary amino radical, a secondary amino radical NHB, or a tertiary amino radical-N(B,B'), wherein B and B', identical or different represent an alkyl group of 1 to 6 carbon atoms, a SH or SB radical, wherein B is defined above, a -CH2OH, -CH(B)OH, -C(B,B')OH radical or the corresponding esters and ethers, a cyclic radical of 3 to 6 carbon atoms or an oxygen, nitrogen or sulfur containing heterocycle such as furan, pyrrole or thiophene, or their salts with metal ions or amine complexes, esters of formula -COOR2, wherein R2 is an alkyl radical of 1 to 3 carbon atoms, amides of the formula COR3 wherein R3 is a primary, secondary and/or tertiary amine and wherein R3 is a secondary or tertiary amine said primary or tertiary amine is substituted by an alkyl group or alcohol of 1 to 4 carbon atoms or their complexes with physiologically acceptable salts wherein said N-substituted pyrrole derivatives are racemates or are optically active isomers, with the proviso that R1 is not hydrogen when R is a derivative selected from the group consisting of glycine, leucine, phenylalanine, tyrosine, serine and glutamic acid.
FIELD: medicine, neurosurgery. SUBSTANCE: for dura mater's transplant one should use analogous brephotissue its size being greater than cranial defect. One should carry out drilling in a bone at the edge of cranial defect. Dura mater's transplant center by ligatures made of prolongly resolving material through channels perforated in plate's center. Osseous defect should be closed with a plate to be fixed with ligatures to bones through channels perforated in them. Moreover, cranial defect in wound is applied with sterile transparent and flexible film to apply marks of cranial defect contours onto it together with openings of perforated channels in bones and plate. Then dura mater's transplant together with adjacent film is cut beyond the contour and film marks. Then one should direct ligatures through film marks of openings and, simultaneously, through transplant, film is removed, and transplant should be fixed by ligatures through osseous channels to internal cranial surface. The method enables to increase efficiency of therapy due to more accurate cutting of dura mater by taking into consideration defect's shape and disposition of channels perforated in bones and, also, accuracy in directing fixation ligatures. EFFECT: higher efficiency of substitution. 1 cl
Argatroban formulations and methods of making and using the formulations are provided. In an embodiment, the present disclosure provides a solid-state salt formulation of argatroban. Upon reconstitution, the solid-state argatroban forms a solution that can be essentially free of particles and suitable for administration. The solid-state argatroban can be in a crystalline and/or amorphous form. The solid-state argatroban can be packaged in a sealed container that may be aseptically-filled to reduce the microbiological burden of the formulation. The solid-state argatroban can be reconstituted with a solution and administered to persons needing same.
PURPOSE: The use of noninvasive respiratory support- namely high flow of oxygen delivered via nasal cannula (HFNC), continuous positive airway pressure (CPAP), and noninvasive ventilation (NIV) - has been expanding in recent years. The physiologic mechanisms underlying each of these forms of support are generally well understood. In contrast, the effects on the sensorimotor mechanisms of swallowing movements, and of breathing and swallowing coordination ─ critical elements of airway protection and bolus clearance ─ remain unclear. The purpose of this systematic review is to assess the existing evidence about the impact of noninvasive respiratory support on swallowing mechanics, airway protection, and respiratory-swallowing patterns in adults.
METHODS: Six databases (PubMed, EMBASE, Web of Science, Scopus, CINAHL and ProQuest Dissertations & Theses) were searched using predetermined terms. Inclusion criteria were: 1) adult humans 2) use of noninvasive respiratory support, and 3) assessment of swallowing.
RESULTS: We identified 8727 articles for screening; 15 met the inclusion criteria. Six studies assessed noninvasive respiratory support in healthy adults, and 9 assessed participants with heterogenous respiratory diagnoses including chronic obstructive pulmonary disease (COPD), obstructive sleep apnea (OSA), acute respiratory failure, and chronic respiratory failure due to neuromuscular disease. Risk of bias was assessed using a modified NIH Quality Assessment Tool. In healthy adults, results demonstrated mixed effects of HFNC and CPAP on measures of swallowing function, airway protection, and respiratory swallowing patterns. Negative effects on respiratory-swallowing patterns were reported with NIV. In adults with heterogeneous respiratory diagnoses, six studies reported that HFNC, CPAP, or nasal NIV improved measures of swallowing and respiratory-swallowing patterns. HFNC has mixed effects on swallowing measures in ICU patients. NIV increased atypical respiratory-swallowing patterns in patients with stable COPD.
CONCLUSIONS: Due to small sample sizes and the wide variation in study designs, the impact of noninvasive respiratory support on swallowing, airway protection, and respiratory-swallowing patterns cannot be confidently assessed based on the current evidence. Future studies using standardized, validated, and reproducible methods to assess the impact of noninvasive respiratory support on swallowing physiology and airway protection are warranted.
Subjects received Menjugate vaccine and Infanrix-hexa vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menjugate and Infanrix-hexa vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
Brain tumors and leukemia are the most common malignancies among children and adolescents in the U.S. Adequate information on the role of inherited genetic susceptibility and environmental exposures in the development of neoplasms in children and adolescents is lacking. In Taiwan, four large petrochemical industries are located in the Kaohsiung metropolitan area. These facilities are proximal to residential areas because of the high population density in the region. Data have shown that the concentrations of ambient polycyclic aromatic hydrocarbons (PAH) and volatile organic compounds (VOC) around the petrochemical industries are at least 10 and 2 times, respectively, higher than those in U.S. industrialized communities. Our preliminary case-control study in metropolitan Kaohsiung showed that young residents (under age 30) living within 3 kilometers of the vicinity of petrochemical industries have a 6.0 fold increase in brain neoplasms and a 2.9 fold increase in leukemia. The purpose of this proposal is to examine the association of exposure to air contaminants (PAH and VOC) emitted from the petrochemical industries, specific genetic polymorphisms (P4501A1 (MspI \& exon 7) and GSTM1 \&T1) from study subjects and their parents, and the risks of brain tumors and leukemia among children and youths in metropolitan Kaohsiung. Our hypothesis is that there is an increased risk of brain tumors and leukemia in patients with high cumulative exposure to these hazards, and that heritable polymorphisms in several genes modify this association. In addition to an independent association of environmental and genetic factors with brain neoplasms and leukemia, we hypothesize that there is greater risk associated with the presence of combined environmental exposure and the high risk genotype. Also, we will assess the role of parental genetic polymorphisms in the development of cancer in their siblings. This proposed study uses an environmental molecular epidemiologic approach, utilizing prospective enrollment of a cohort of brain tumor and leukemia subjects in a population-based case-control design. This proposal is responsive to the recommendation of the National Research Council that risk assessment and public health policy pay special attention to the protection of children.
BACKGROUND: Limited research has been conducted to specifically investigate the identification of risk factors and the development of prediction models for lateral lymph node metastasis (LNM) in pediatric and adolescent differentiated thyroid carcinoma (DTC) populations, despite its significant association with unfavorable prognosis.
METHODS: This study entails a retrospective analysis of the clinical characteristics exhibited by pediatric and adolescent patients who have been diagnosed with DTC. The data utilized for this analysis was sourced from the Surveillance, Epidemiology, and End Results (SEER) database, spanning the time frame from 2000 to 2020. Furthermore, the study incorporates patients who were treated at the Departments of Breast and Thyroid Surgery in the Second Clinical Medical College, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine, as well as The General Hospital of Western Theater Command, during the period from 2010 to 2020.
RESULTS: A cohort of 2631 patients from the SEER database, along with an additional 339 patients from our departments who met the specified inclusion criteria, were included in this study. Subsequently, four clinical variables, namely age, tumor size, multifocality, and extrathyroidal invasion, were identified as being significantly associated with lateral LNM in pediatric and adolescent DTC patients. These variables were then utilized to construct a nomogram, which demonstrated effective discrimination with a concordance index (C-index) of 0.731. Furthermore, the performance of this model was validated through both internal and external assessments, yielding C-index values of 0.721 and 0.712, respectively. Afterward, a decision curve analysis was conducted to assess the viability of this nomogram in predicting lymph node metastasis.
CONCLUSION: The current investigation has effectively constructed a nomogram model utilizing visualized multipopulationsal data. Our findings demonstrate a significant association between various clinical characteristics and lateral LNM in pediatric and adolescent DTC patients. These outcomes hold substantial significance for healthcare practitioners, as they can employ this model to inform individualized clinical judgments for the pediatric and adolescent cohorts.
The invention relates to the field of medicinal preparations, in particular to a method for preparing xanthan gum olsalazine colon-specific sustained release tablets. In recent years, a ulcerative colitis is treated by using olsalazine at abroad, and a good curative effect is achieved. The olsalazine is formed by connecting molecular salicylic acids by an azo bond, and is cracked to form dimolecular 5-aminosalicylic acid in colons by bacteria to exert an effect, so the effective time of medicinal concentration in the colons is prolonged by a new technology to improve the bioavailability of the olsalazine; and therefore, the curative effect is ensured, the toxic and side effects are reduced, and the compliance of patients also can be increased by reducing the times of administration. Therefore, the xanthan gum olsalazine colon-specific sustained release tablets are needed to be prepared. In the dissolving-out process, outer layer membranes are dissolved and dispersed first, rear tablet cores are dissolved, and medicines are released slowly. The medicine release delay time interval of a medicine release system is irrelevant with the in-vivo normal physiological conditions of subjects, and the medicines enter the colons after 3.5 hours averagely and are released slowly and uniformly within 6 hours. The xanthan gum olsalazine colon-specific sustained release tablets consist of the tablet cores and coatings.
Families randomized to the IA condition will receive 17 in-home sessions. These include a one-time start up session followed by twice-weekly visits in which they will be coached on how to implement the IA strategies. Families will receive a set of developmentally appropriate toys.
Proteases generally tend to reduce the activity of coagulation factor VIII by degrading the molecule. The present invention relates to a process for reducing the detrimental influence of metal-dependent proteases upon recombinant factor VIII molecules, by adding an inhibitor of metal-dependent proteases to a solution after harvest. The solution is suitably the harvest solution or any aqueous solution being fed to or leaving the primary isolation, being the initial step of the purifying sequence. The inhibitor is selected from: i) complexing agents with a stronger affinity for the metal ion of the protease than for the ion or ions stabilizing the factor VIII molecule and ii) compounds structurally related to the natural substrate of the protease and containing an electronegative moiety. The presence of an inhibitor, preferably a complexing agent, after harvest allows for a prolonged harvest period and considerably higher yield with essentially retained factor VIII activity. The invention further relates to an aqueous solution containing recombinant factor VIII which has been purified according to the present process and use of such an aqueous solution, for the manufacture of a medicament for administration to a patient having the symptoms of hemophilia. Also, the invention relates to a method for treatment of hemophilia by administration of a therapeutically effective amount of recombinant factor VIII which has been purified according to the present process.
Obesity is an epidemic worldwide. Overweight and multiple obesity-related mechanisms, including dysmetabolic alterations, contribute to cardiovascular deleterious effects. Hence, overweight and obesity have been independently associated with increased cardiovascular risk, whose assessment is crucial for preserving life quality and reducing mortality, and to address appropriate therapeutic strategies in obese patients. Beyond the standard of care in managing overweight and obesity in adults (i.e., diet and physical exercise), several relevant pharmacotherapies have been approved, and several procedures and device types for weight loss have been recommended. In such a contest, medical weight management remains one option for treating excess weight. Most drugs used for obesity reduce appetite and increase satiety and, secondarily, slow gastric emptying to reduce body weight and, therefore, act also to improve metabolic parameters. In this contest, agonists of the glucagon-like peptide-1 receptor (GLP-1RAs) modulate different metabolic pathways associated with glucose metabolism, energy homeostasis, antioxidation, and inflammation. Moreover, this class of drugs has shown efficacy in improving glycemic control, reducing the incidence of cardiovascular events in type 2 diabetic patients, and reducing body weight independently of the presence of diabetes. Recently, in overweight or obese patients with pre-existing cardiovascular disease but without diabetes, the GLP-1RA semaglutide reduced the incidence of cardiovascular and cerebrovascular events and death from cardiovascular causes. Thus, semaglutide has been approved for secondary prevention in obese people with cardiovascular disease. Nevertheless, whether this class of drugs is equally effective for primary prevention in obese people has to be demonstrated. In this review, we will summarize updates on the pathophysiology of obesity, the effects of obesity on cardiovascular risk, the impact of different obesity phenotypes on cardiovascular diseases, and the novelties in the clinical management of obesity for cardiovascular prevention.
Before the procedure, women will be asked to fill out a Personal Information Form (PIF), Psychological Well-being Scale (PWS), Menopause Symptoms Assessment Scale (MSAS), and Menopause Attitude Assessment Scale (MAAS) (1st Measurement). Women in the control group will be provided with information about routine menopausal symptoms. 2 months later, the 2nd Measurement will be taken. After the follow-up measurement is taken for the control group, counseling will be provided to women according to their needs (addressing problems, answering questions, providing information as needed).
BACKGROUND: Cervical cytology has been the primary method of cervical cancer screening for decades. Tests that detect viral HPV are shown in several randomized trials to provide better protection against cancer compared with cytology. HPV-based screening has been implemented alongside cytology in the Nordic countries for several years. The aim of this study was to compare cytology and HPV-based screening in the colposcopy referrals and detection rates of cervical lesions.
METHODS: Individual-level screening data from Finland, Iceland, Norway and Sweden were harmonized and aggregated locally. We utilized data for tests taken during years 2015-17 and biopsies taken during years 2015-19 to allow 24 months of follow-up. Age-standardized estimates and age-adjusted risk ratios for six different outcomes of screening management were calculated.
RESULTS: The age-standardized colposcopy rates were higher in HPV-based testing compared with cytology in Finland (3.5% vs. 0.9%) and Norway (6.0% vs. 4.1%) but lower in Sweden (3.7% vs. 4.9%). The relative detection rate of cervical intraepithelial neoplasia grade 2 and above in HPV-based testing compared with cytology was highest in Finland (RR 2.37, 95% CI 2.13-2.63) and Norway (RR 1.66, 95% CI 1.57-1.72) while in Sweden the difference was not statistically significant (RR 0.98, 95% CI 0.95-1.00).
CONCLUSIONS: The effects of implementing HPV screening varied by country as different screening algorithms were implemented. HPV-based screening increases colposcopy rates mainly through referrals from increased repeat testing and detection rate is therefore significantly higher compared with cytology. Monitoring of these indicators in subsequent rounds of HPV-based screening remains essential.
Initial IV infusion of ustekinumab at baseline followed by one subcutaneous injection at Week 8. In participants who demonstrate an allergic reaction to the baseline IV infusion, the second dose at Week 8 can also be administered as an IV infusion instead of a subcutaneous injection.
The MOSAIC observational study will measure activity in critically ill patients for up to 28 days in the hospital using two different, objective measures, a clinical mobility scale and accelerometry. We will evaluate the independent association between activity and outcomes 3 and 12 months after ICU discharge. Specifically, Aim 1 will determine the relationship between activity and disability in ADLs and mobility. Aim 2a will determine the relationship between activity and physical and cognitive function. Aim 2b will evaluate physical and cognitive function as mediators of long-term disability. Aim 3a will determine the relationship between activity and biomarkers of inflammation and coagulation. Aim 3b will determine the relationship between these biomarkers of inflammation and coagulation and disability, physical and cognitive function.
Target ORi™ of 0.15, check the ORi™ every 5 minutes and adjust the inspired oxygen concentration in 5% increments. If the ORi™ decreases to less than 0.15, treat it in the same way as if hypoxia occurred in the conventional group.
PURPOSE: A cosmetic composition for skin anti-aging containing an oligo-peptide mixture stabilized on a nano liposome and a liquid crystal base is provided to stably inject the oligopeptide mixture for improving skin-moisture effect and anti-wrinkle effect. CONSTITUTION: A cosmetic composition for skin anti-aging is a mixture containing an oligo-peptide mixture stabilized on a nano liposome and a liquid crystal base produced using lecithin, ceramide, cholesterol or their derivatives. The oligo-peptide mixture is a mixture of hexapeptide, acetyl tetra peptide and pentapeptide. The content rate of the oligo-peptide mixture is 0.1~60.0wt% by the entire weight of the cosmetic composition. The oligo-peptide mixture is contained in 0.01~1wt% by the entire content of the nano liposome. The content rate of the liquid crystal base is 20~99.9wt%.
Browning of white adipose tissue (WAT) is become an appealing target for therapeutics in the treatment of obesity and related metabolic diseases. Dapagliflozin is widely used in the treatment of type 2 diabetes, and it is also found that the drug exhibits regulate systemic metabolism such as obesity, insulin resistance and hepatic steatosis. However, the precise role of dapagliflozin on WAT remodeling remains to be elucidated. The current study aimed to explore the role of dapagliflozin on WAT browning in high-fat diet (HFD)-induced obese mice. Male C57BL/6J mice (n = 6 per group) were used to establish obesity model by following feeding with HFD for 6 weeks. The mice were randomly treated with or without dapagliflozin for the experimental observation. The volume and fat fraction of WAT were quantified, H&E, UCP-1 staining and immunohistochemistry were conducted to investigate the white-to-brown fat conversion and angiogenesis in WAT respectively. Quantitative real-time polymerase chain reaction (qPCR) was employed to explore the mRNA expression levels of genes related to fat browning and angiogenesis in WAT. Subsequently, 3T3-L1 cells were used to explore the effect of dapagliflozin on preadipocytes differentiation in vitro. Our results demonstrated that dapagliflozin could reduce body weight gain and promote WAT browning in HFD induced obese mice via regulating lipogenesis and angiogenesis in WAT. Furthermore, dapagliflozin reduce cells differentiation, up-regulate the expression of WAT browning and angiogenesis genes in 3T3-L1 adipocytes in vitro. In conclusion, dapagliflozin can potentially promote WAT browning in HFD induced obese mice via improving lipogenesis and angiogenesis in WAT.
PROBLEM TO BE SOLVED: To efficiently transfer data in an image transfer system for transferring medical image data between terminals and an image server by a DICOM specification communication system. SOLUTION: Relay servers P1 and P2 are provided among terminals T1-Tn and an archiver 1 and a data base 2. When a request for the transfer of medical image data is inputted to the terminal T1, and transmitted to the relay server P1, the relay server P1 transmits the request for the transfer of required medical image data to the archiver 1 in response to the request from the terminal T1. The archiver 1 transfers the required medical image data to the relay server P1. The relay server P1 stores the medical image data in a cache C1, and transfers the medical image data to the terminal T1. Thus, the terminal T1 can display the desired medical image data on a CRT for executing diagnosis.
Cognitive Behavioral Treatment-Insomnia. 8 Session treatment focusing on behavior and cognitions related to sleep and pain.
Approximately 500 individuals who do not have a positive COVID-19 test (nasal swab, serological antibody assay, etc.) but who have experienced COVID-19 symptoms and have strong epidemiologic links suggesting probable COVID-19 infection (such as household or occupational contacts and close timing of their symptoms to an index case) will be invited to participate.